Synovial sarcoma is a rare malignancy of mesenchymal origin, characterized by a chromosomal translocation, t(X;18) (p11.2;q11.2). Wide surgical resection with radiation and cytotoxic chemotherapy is established as a standard treatment; however synovial sarcoma remains a high-grade sarcoma with poor prognosis, and novel anti-cancer agents and immunological approaches are currently being developed. The patient-derived cell line is a critical tool for basic and pre-clinical research. However, only a few patient-derived synovial sarcoma cell lines are publicly available from cell banks. Thus, the aim of this study was to establish and characterize a novel cell line for synovial sarcoma. Using a surgically resected tumor tissue from a 48-year-old female patient, we successfully established a cell line, named NCC-SS3-C1. NCC-SS3-C1 cells harbor an SS18-SSX1 fusion gene and exhibit moderate growth, spheroid formation, and invasion. We examined a range of proliferation-inhibiting effects of small molecule anti-cancer compounds, including FDA-approved anti-cancer drugs, using NCC-SS3-C1 cells, and identified anti-cancer drugs which inhibited the proliferation of NCC-SS3-C1 cells at the low concentration. We concluded that NCC-SS3-C1 would be a useful tool for basic and pre-clinical synovial sarcoma research.

中文翻译：

---

NCC-SS3-C1的建立和表征：一种新型的患者滑膜肉瘤细胞系。

滑膜肉瘤是间充质起源的一种罕见恶性肿瘤，其特征是染色体易位，t（X; 18）（p11.2; q11.2）。标准的治疗方法是采用放射线和细胞毒性化学疗法进行广泛的手术切除；然而，滑膜肉瘤仍是预后较差的高级别肉瘤，目前正在开发新型抗癌药和免疫学方法。患者来源的细胞系是基础和临床前研究的重要工具。但是，只有少数患者来源的滑膜肉瘤细胞系可从细胞库中公开获得。因此，本研究的目的是建立和表征滑膜肉瘤的新型细胞系。使用来自48岁女性患者的手术切除的肿瘤组织，我们成功建立了一个名为NCC-SS3-C1的细胞系。NCC-SS3-C1电池带有SS18-SSX1融合基因，并表现出适度的生长，球状体形成和侵袭。我们使用NCC-SS3-C1细胞检查了包括FDA批准的抗癌药在内的小分子抗癌化合物的一系列增殖抑制作用，并确定了抑制NCC-SS3-C1增殖的抗癌药物。细胞处于低浓度。我们得出的结论是，NCC-SS3-C1将是基础和临床前滑膜肉瘤研究的有用工具。